Dana–Farber/Harvard Cancer Center

The Dana–Farber/Harvard Cancer Center is the largest National Cancer Institute (NCI) designated Comprehensive Cancer Center in the nation. Founded in 1997, DF/HCC is an inter-institutional research enterprise that unites all of the cancer research efforts of the Harvard affiliated community. The primary goal of the Cancer Center is to encourage and promote collaborative interactions and translational research that will lead to new approaches to cancer prevention, diagnosis, and treatment.

DF/HCC’s members pool their extensive experience and acclaimed expertise in all aspects of cancer research. They carry out their research in disease site- and discipline-based research programs that cross both institutional and scientific boundaries.

DF/HCC is one of just 39 NCI designated Comprehensive Cancer Centers. Its members hail from the following institutions: Beth Israel Deaconess Medical Center, Brigham and Women’s Hospital, Boston Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Harvard School of Public Health, Massachusetts General Hospital, and St. Elizabeth's Medical Center.[1]

References
  1. "NCI Cancer Centers Program". Archived from the original on 2008-05-05. Retrieved 2007-06-07.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.